Holen Sie sich die Stockscreener-App
7.55
2.45%
-0.19
Handel nachbörslich:
7.55
Schlusskurs vom Vortag:
$7.74
Offen:
$7.75
24-Stunden-Volumen:
71,118
Relative Volume:
0.63
Marktkapitalisierung:
$257.86M
Einnahmen:
$21.25M
Nettoeinkommen (Verlust:
$-16.05M
KGV:
-12.38
EPS:
-0.61
Netto-Cashflow:
$-17.14M
1W Leistung:
-7.81%
1M Leistung:
-8.48%
6M Leistung:
-4.43%
1J Leistung:
+31.99%
1-Tages-Spanne:
$7.43
$7.88
1-Wochen-Bereich:
$7.3501
$8.235
52-Wochen-Spanne:
$4.68
$9.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Firmenname
Fennec Pharmaceuticals Inc
Sektor
Branche
Telefon
(919) 636-4530
Adresse
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Vergleichen Sie FENC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
7.55 | 265.71M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-08 | Fortgesetzt | Craig Hallum | Buy |
| 2020-06-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-11 | Eingeleitet | Goldman | Buy |
Fennec Pharmaceuticals Inc Aktie (FENC) Neueste Nachrichten
What hedge fund moves indicate for Fennec Pharmaceuticals Inc. (RV41) stockQuarterly Portfolio Report & Safe Investment Capital Preservation Plans - Newser
Will Fennec Pharmaceuticals Inc. (RV41) stock hit Wall Street targetsTake Profit & Fast Entry High Yield Tips - Newser
Can Fennec Pharmaceuticals Inc. (RV41) stock withstand sector downturns2025 Trade Ideas & Expert Verified Stock Movement Alerts - Newser
How analysts revise price targets for Fennec Pharmaceuticals Inc. (RV41) stockJuly 2025 Breakouts & Safe Entry Point Identification - Newser
(FENC) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Will Fennec Pharmaceuticals Inc. (RV41) stock benefit from Fed rate cutsDay Trade & Smart Allocation Stock Reports - Newser
Why Fennec Pharmaceuticals Inc. stock is popular among millennialsMarket Weekly Review & Daily Volume Surge Signals - Newser
(FRX) Technical Pivots with Risk Controls (FRX:CA) - news.stocktradersdaily.com
Is Fennec Pharmaceuticals Inc. stock resilient to inflationInflation Watch & Fast Entry Momentum Alerts - Newser
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Can Fennec Pharmaceuticals Inc. stock attract ESG capital inflows2025 Bull vs Bear & Technical Pattern Based Buy Signals - Newser
Stocks in play: Fennec Pharmaceuticals Inc. - The Globe and Mail
Fennec Pharmaceuticals Inc Announces Positive Results from PEDMARK® Trial in Japan - TradingView
Wedbush on Fennec Pharmaceuticals Latest Japan Trial Results - marketscreener.com
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power - Benzinga
Fennec Pharmaceuticals Inc. Announces Positive Topline Results from Investigator-Initiated Clinical Study of Pedmark®? in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Says its Phase 2/3 Trial of Pedmark in Japan Meets Primary Endpoint - MarketScreener
Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan - TipRanks
Fennec’s pediatric hearing protection drug shows positive results in Japan By Investing.com - Investing.com Australia
Fennec Pharmaceuticals Brief: Announcing "Positive" Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss - The Manila Times
Is Fennec Pharmaceuticals Inc. (RV41) stock a buy before new product rolloutQuarterly Trade Report & Daily Stock Trend Reports - Newser
(FRX) Long Term Investment Analysis (FRX:CA) - news.stocktradersdaily.com
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) Price Target at $13.33 - Defense World
(FRX) Technical Data (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - The Globe and Mail
Loss-Making Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Expected To Breakeven In The Medium-Term - Yahoo Finance
Trend Tracker for (FRX) (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals highlights cisplatin ototoxicity risks - Traders Union
(FENC) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Why Some Analysts Are Raising Price Targets on Silkflex Polymers India LimitedStochastic Oscillator Alerts & Capital Efficiency Improvement - earlytimes.in
(FRX) Strategic Investment Report (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals Completes Full Debt Redemption, Strengthening Financial Position - MSN
Is Fennec Pharmaceuticals Inc. (RV41) stock attractive post correctionTrade Volume Report & Consistent Profit Focused Trading Strategies - newser.com
How Fennec Pharmaceuticals Inc. (RV41) stock performs in volatility spikesWatch List & Daily Entry Point Trade Alerts - newser.com
Will Fennec Pharmaceuticals Inc. stock benefit from commodity pricesJuly 2025 Sentiment & Free Risk Controlled Daily Trade Plans - newser.com
How Fennec Pharmaceuticals Inc. (RV41) stock trades pre earningsJuly 2025 Action & AI Enhanced Trading Alerts - newser.com
What dividend safety score for Fennec Pharmaceuticals Inc. stockJuly 2025 Fed Impact & High Yield Stock Recommendations - newser.com
Southpoint Capital Advisors LP sells Fennec Pharmaceuticals shares By Investing.com - Investing.com India
Southpoint Capital Advisors LP sells Fennec Pharmaceuticals shares - Investing.com
Fennec Pharmaceuticals Closes $5M Private Offering in Canada - MSN
Why Fennec Pharmaceuticals Inc. (RV41) stock is favored by hedge fundsPortfolio Risk Report & Real-Time Market Trend Scan - newser.com
Finanzdaten der Fennec Pharmaceuticals Inc-Aktie (FENC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fennec Pharmaceuticals Inc-Aktie (FENC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Southpoint Capital Advisors LP | 10% Owner |
Nov 14 '25 |
Sale |
8.00 |
160,100 |
1,280,432 |
3,850,000 |
| Southpoint Capital Advisors LP | 10% Owner |
Nov 17 '25 |
Sale |
8.79 |
85,918 |
755,193 |
3,764,082 |
| Raykov Rosty | Director |
Nov 05 '25 |
Sale |
8.10 |
10,000 |
81,000 |
82,318 |
1.44%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):